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To the Editor,
Repetitive transcranial magnetic stimulation (rTMS) is a well-established treatment for medically refractory major depressive disorder (MDD), using powerful, focused magnetic pulses (1.0-2.5 Tesla) delivered through an electromagnetic coil to stimulate the dorsolateral prefrontal cortex (DLPFC) [1] . rTMS is a safe procedure, with side-effects usually limited to scalp pain during stimulation, transient and mild headache and fatigue after stimulation, and rare seizures (<0.1%) [1] . Although uncommon, eye symptoms such as pain or discomfort have also been reported [2, 3] . The development of sight-threatening conditions are rare, with a single case in the literature reporting the development of a retinal tear following rTMS [4] . In this letter, we describe the occurrence of posterior vitreous detachment (PVD) and retinal tear in a patient receiving rTMS and provide recommendations for ocular screening and management in these cases.
CASE DESCRIPTION
A 50-year-old female patient with a 6-year history of medically refractory MDD was referred for rTMS. Medication history included 5 unsuccessful trials of antidepressant medication at optimal dosage and of adequate duration, as well as psychotherapy. Past medical and ophthalmological history were unremarkable, with no rTMS contraindications.
The patient underwent daily rTMS sessions of bilateral theta burst stimulation (TBS), consisting of continuous TBS (cTBS) stimulation over the right DLPFC (triplet 50 Hz bursts, 5 per second, 600 pulses, 40 seconds total) followed by intermittent TBS (iTBS) stimulation over the left DLPFC (600 pulses per session, 2s on and 8s off, 3 m 9 s total). Treatment was delivered using a MagPro R30 device with a Cool-B70 coil (MagVenture, Farum, Denmark) using the adjusted BeamF3/F4 algorithm for targeting [5] . Treatment was administered at 120% of resting motor threshold (rMT), which was 54% of maximum stimulator output on the right side and 48% on the left side. During treatment, the reported pain on the verbal rating scale (VRS) averaged 8 out of 10 (VRS scale 0-10, 10 = maximum tolerable pain). The initial course was planned for 30 sessions, but the patient reported increased ocular pain, floaters and a superotemporal shadow in her left eye following the 25 th session; treatment was discontinued, and the patient referred to the ophthalmology team. (Fig. 1) .
DISCUSSION
The vitreous is a clear matrix composed of collagen fibrils, hyaluronic acid and of 99% water located between the lens and the retina [6] . Enzymatic and nonenzymatic processes, and a reduction in the network density of collagen fibrils may lead to vitreous liquefaction and shrinkage of the gel, which ultimately results in separation of the vitreous from the retina. This phenomenon referred to as a PVD is typically an age-related process, usually occurring in patients over the age of 50 years. However, certain risk factors, including trauma, can result in an earlier development of PVD. The most frequent symptoms related with acute PVD are floaters and photopsias [6, 7] . During the evolution of a PVD, the vitreous may cause traction on certain areas of the retina, which can result in a retinal tear [7] . Symptomatic retinal tears require prompt treatment as these can lead to retinal detachments [7, 8] .
In landmark rTMS clinical trials, eye pain was reported in 6.1% of patients either during or after sessions, but no mention of visual symptoms were made [2, 9] . In this patient, based on the temporal relationship between the onset of symptoms one day after an rTMS treatment, and given that these findings were not present in her recent eye exam prior to rTMS, it is possible that rTMS precipitated or accelerated the development of a PVD and a large retinal tear. The mechanism of how rTMS resulted in a retinal tear in this case is unknown, however it is most likely related to the repetitive saccades secondary to facial and ocular muscle contraction that occurs throughout multiple treatment sessions. The repetitive saccades may result in disorganization of collagen fibrils, vitreous liquefaction and, consequently, in the development of an acute PVD. Once the PVD occurs, ongoing repetitive saccades likely results in vitreous traction on the retina and a subsequent retinal tear. Consistent with theory, other studies have suggested that repetitive saccades lead to increased tractional forces on the peripheral retina in the setting of a PVD [10] . However, it is not clear what specific factors might have increased this patient's vulnerability to injury compared to the general rTMS population. Indeed, it is important to underline the rarity of such cases in the published literature, with this report being the second one to date [4] ; this event was the first noted in >40 000 cumulative sessions for the clinic treating this patient.
RECOMMENDATIONS
Patients receiving rTMS should be carefully followed and actively questioned in regard to ophthalmological symptoms such as floaters and photopsia, and the presence of these symptoms at baseline should be documented before initiating rTMS. should be withheld pending ophthalmological examination [7] . In the event that the patient develops a retinal tear or retinal detachment attributed to rTMS, it may be advisable to discontinue future treatment.
